Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease.

IF 3.6 3区 医学 Q2 HEMATOLOGY Transplantation and Cellular Therapy Pub Date : 2024-11-11 DOI:10.1016/j.jtct.2024.11.004
Zachariah DeFilipp, Laura Fox, Tobias A W Holderried, Varun Mehra, David Michonneau, Alex Pashley, Andrei Karlsson, Dennis Dong Hwan Kim
{"title":"Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease.","authors":"Zachariah DeFilipp, Laura Fox, Tobias A W Holderried, Varun Mehra, David Michonneau, Alex Pashley, Andrei Karlsson, Dennis Dong Hwan Kim","doi":"10.1016/j.jtct.2024.11.004","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review (SLR) was conducted according to PRISMA guidelines, followed by a feasibility assessment (FA) to assess potential between-study heterogeneity in the meta-analysis (MA). Random-effects MAs were performed for overall survival (OS), failure-free survival (FFS), overall response rate (ORR) and skin-specific response. A subgroup analysis was conducted to explore the effect of NIH assessment criteria. The SLR identified 627 records; 45 unique studies were ultimately included in the MA. For patients treated with ECP, at Month 12, the pooled OS rate was 83.97% and the pooled FFS rate was 60.79%. ORR was 45.34% at Months 3-4 and 58.23% at Months 6-8. Subgroup analyses showed no significant difference in ORR between studies utilizing NIH criteria and those utilizing non-NIH criteria. Skin-specific response was 34.86% at Months 2-3 and 54.22% at Months 4-6. There was considerable heterogeneity across all analyses, with I<sup>2</sup> values ranging from 65% to 91%. This SLR and MA indicates that ECP results in favorable outcomes in the treatment of SR-cGvHD, including OS, FFS and ORR.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2024.11.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review (SLR) was conducted according to PRISMA guidelines, followed by a feasibility assessment (FA) to assess potential between-study heterogeneity in the meta-analysis (MA). Random-effects MAs were performed for overall survival (OS), failure-free survival (FFS), overall response rate (ORR) and skin-specific response. A subgroup analysis was conducted to explore the effect of NIH assessment criteria. The SLR identified 627 records; 45 unique studies were ultimately included in the MA. For patients treated with ECP, at Month 12, the pooled OS rate was 83.97% and the pooled FFS rate was 60.79%. ORR was 45.34% at Months 3-4 and 58.23% at Months 6-8. Subgroup analyses showed no significant difference in ORR between studies utilizing NIH criteria and those utilizing non-NIH criteria. Skin-specific response was 34.86% at Months 2-3 and 54.22% at Months 4-6. There was considerable heterogeneity across all analyses, with I2 values ranging from 65% to 91%. This SLR and MA indicates that ECP results in favorable outcomes in the treatment of SR-cGvHD, including OS, FFS and ORR.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗类固醇难治性慢性移植物抗宿主病的体外射血疗法的系统性回顾和荟萃分析》(Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease)。
本荟萃分析(MA)旨在评估体外光动力疗法(ECP)治疗类固醇难治性慢性移植物抗宿主病(SR-cGvHD)的有效性和安全性。根据PRISMA指南进行了系统性文献综述(SLR),随后进行了可行性评估(FA),以评估荟萃分析(MA)中潜在的研究间异质性。对总生存期(OS)、无失败生存期(FFS)、总反应率(ORR)和皮肤特异性反应进行了随机效应荟萃分析。还进行了亚组分析,以探讨 NIH 评估标准的影响。SLR确定了627条记录,最终有45项独特的研究被纳入MA。对于接受 ECP 治疗的患者,在第 12 个月,汇总 OS 率为 83.97%,汇总 FFS 率为 60.79%。第 3-4 个月的 ORR 为 45.34%,第 6-8 个月为 58.23%。分组分析表明,采用 NIH 标准和非 NIH 标准的研究在 ORR 方面没有明显差异。皮肤特异性反应在第 2-3 个月为 34.86%,在第 4-6 个月为 54.22%。所有分析都存在相当大的异质性,I2 值从 65% 到 91% 不等。该SLR和MA表明,ECP在治疗SR-cGvHD方面取得了良好的疗效,包括OS、FFS和ORR。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
期刊最新文献
Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplantation and Cellular Therapy 29/3 (2023) 204-204]. Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS. Factors Associated with Increased Risk of Contamination in Bone Marrow Transplants. Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease. Outpatient management of patients conditioned with Fludarabine and Treosulfan prior to allogeneic hematopoietic cell transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1